NFL Biosciences: A Biomarker Revitalizes the Clinical Potential of NFL-101 for Smoking Cessation
On Monday, NFL Biosciences released analysis results of its drug candidate NFL-101 conducted in a sub-population defined by a predictive biomarker. This personalized medicine approach modifies the clinical development strategy and reshapes the commercialization stakes for the biotech company based in Montpellier.
Increased Efficacy in 57% of the Target Population
Out of 306 patients in the CESTO2 study, 57.2% exhibit the biomarker defined as an IgG1 level below 200 ng/mL. In this target population, NFL-101 achieves 36.1% continuous abstinence at 4 weeks (measured by expired CO) compared to 19.0% for the placebo, a risk ratio of 1.90 (p = 0.033). Over the same period, measured by urinary cotinine, efficacy increases to 29.5% versus 12.1% with the placebo, with a risk ratio of 2.44 (p = 0.016).
In patients not carrying the biomarker (43% of the sample), NFL-101 does not show statistical superiority over the placebo. This distinction confirms that the therapeutic gain is not due to a variation in placebo response, but a true effect of the treatment limited to the biomarker-positive sub-population.
An Indirect Comparison Favors NFL-101 Over Champix
The press release offers an indirect comparison with the EAGLES study, a benchmark study in tobacco addiction. Over the period considered most relevant (3 months post-treatment), NFL-101 in the target population shows 27.9% continuous abstinence measured by expired CO, approximately 30% higher than that of Champix observed in EAGLES (21.8%). NFL Biosciences also highlights that NFL-101 does not reproduce the adverse effects characteristic of Champix, including nausea and abnormal dreams, and only requires two administrations a week apart compared to a twice-daily treatment over 12 weeks with Champix.
The 12-month efficacy in the target population remains favorable (21.3% for NFL-101 versus 10.3% for the placebo, risk ratio of 2.06), but does not cross the conventional statistical threshold (p = 0.096), an expected result given that CESTO2 was not sized for this endpoint.
Streamlined Phase 3 and Enhanced Partnership Opportunities
The identification of the biomarker drastically reduces the number of participants needed for Phase 3. While a study involving the general population would require about 1,000 participants, a Phase 3 conducted exclusively in the biomarker-positive population could manage with about 450 subjects. This gain in statistical efficiency reduces operational and financial development costs, a crucial element for a small biotech company.
NFL Biosciences confirms incorporating 'biomarker positive' status as an inclusion criterion in the protocols of upcoming studies and continues discussions with regulatory authorities to finalize the exact modalities. The company favors a flexible commercial approach including global licensing partnerships, co-development, or separate agreements based on the geographical or therapeutic interests of potential partners. This clinical crystallization enhances the credibility of its botanical approach among industrial partners. The results of NFL-101 also serve as an internal benchmark to assess the performance of NFL-102 in the TONIC study and prioritize the development efforts of the portfolio.
